BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and...
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and...
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused...
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical...
Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4th largest cannabis...
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501,...
Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune...
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59%Consolidation of Manufacturing Operations Progressing on ScheduleReaffirms Full Year 2026...
ATLANTA, May 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team...
Lake Oswego, Oregon--(Newsfile Corp. - May 12, 2026) - Functional Brands Inc. (NASDAQ: MEHA), (the "Company"), a leading innovator in...
Source plant is widely regarded as one of the most valuable fragrance raw materials in the worldStage 2 contract follows...
Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio...
PALO ALTO, CA / ACCESS Newswire / May 12, 2026 / Bioz, Inc., a trusted platform for embedding scientific validation...